Cyclooxygenase-2 enzyme inhibitors: Place in therapy

American Family Physician

Volumn 61, Issue 12, 2000, Pages 3669-3676

  Noble, Sara L ^a   King, Deborah S ^a   Olutade, Joyce I ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ABDOMINAL PAIN; ARTHRITIS; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; REVIEW;

ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; BLEEDING TIME; BLOOD PLATELETS; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; DUODENAL ULCER; HUMANS; LACTONES; PYRAZOLES; RISK FACTORS; SULFONAMIDES; SULFONES; UNITED STATES;

EID: 0034658978     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions
2. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
3. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
4. NSAID-associated gastrointestinal damage and the elderly. GI disease in the elderly series: Article five in the series
5. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on practice parameters of the American College of Gastroenterology
6. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. The double-edged sword
7. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal
8. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
9. Risk factors for serious non-steroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial
10. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
11. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System
12. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis
13. The induction and suppression of prostaglandin H2 synthase (cydooxygenase) in human monocytes
14. COX-1 and COX-2 tissue expression: Implications and predictions
15. Cyclooxygenases 1 and 2
16. Kinetic basis for selective inhibition of cyclooxygenases
17. Outcome of specific COX-2 inhibition in rheumatoid arthritis
18. The discovery and function of COX-2
19. Celecoxib for arthritis
20. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
21. Rofecoxib for osteoarthritis and pain
22. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
23. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
24. COX-1 spring NSAIDs - Is the enthusiasm justified?
25. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
26. Effects of nonsteroidal anti-inflammatory therapy on platelets
27. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans
28. From the Food and Drug Administration
29. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
30. The clinical potential of cyclooxygenase-2-specific inhibitors
31. COX-2 inhibitors
32. The relationship between cyclooxygenase-2 expression and colorectal cancer
33. Celecoxib is associated with a low rate of clinically significant upper GI events: A two-year open label trial